#Datopotamab
LightNews LightNews
oncodaily.bsky.social
Datopotamab Deruxtecan Improves Outcomes in IO-Ineligible mTNBC - Paolo Tarantino

@ptarantinomd.bsky.social

oncodaily.com/voices/datop...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TNBC #BreastCancer #TROPIONBreast02 #Datroway
Paolo Tarantino: Datopotamab Deruxtecan Improves Outcomes in IO-Ineligible mTNBC - OncoDaily
Paolo Tarantino: Datopotamab Deruxtecan Improves Outcomes in IO-Ineligible mTNBC / Breast Cancer, cancer, datopotamab deruxtecan, Datroway, ESMO25, OncoDaily,
oncodaily.com
October 7, 2025 at 9:36 PM
oncodaily.bsky.social
Press Release: Datopotamab-Deruxtecan Demonstrates Survival Benefit in First-Line Metastatic Triple-Negative Breast Cancer

@astra-zeneca.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TNBC #BreastCancer #Datroway
Datopotamab-Deruxtecan Extends Survival in Metastatic TNBC
Datopotamab-Deruxtecan significantly improves overall survival versus chemotherapy in first-line metastatic triple-negative breast cancer.
oncodaily.com
October 7, 2025 at 9:29 PM
oncodaily.bsky.social
China Approved DATROWAY (Datopotamab Deruxtecan) for HR-Positive, HER2-Negative Metastatic Breast Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DATROWAY #DatopotamabDeruxtecan #BreastCancer #mBC
China Approved DATROWAY (Datopotamab Deruxtecan) for HR-Positive, HER2-Negative Metastatic Breast Cancer - OncoDaily
China approves Datopotamab Deruxtecan (Datroway) for advanced HR-positive, HER2-negative breast cancer after prior therapy.
oncodaily.com
August 26, 2025 at 9:26 PM
oncodaily.bsky.social
Morgan Stanley’s Top Oncology Catalysts for 2025
@astrazeneca.bsky.social
@handle.invalid

oncodaily.com/insight/morg...

#AstraZeneca #AZN #BioNTech #BNTX #Cancer #Datopotamab #Deruxtecan #Gilead #GILD #Ivonescimab #Merck #Moderna #OncoDaily #Oncology #Pfizer #Regeneron #SMMT #Medicine #Health
Morgan Stanley’s Top Oncology Catalysts for 2025 - OncoDaily
Morgan Stanley’s Top Oncology Catalysts for 2025 / Antibody drug conjugates, AstraZeneca (AZN), BioNTech (BNTX), cancer, datopotamab deruxtecan, Gilead
oncodaily.com
December 29, 2024 at 9:47 PM
oncodaily.bsky.social
Datopotamab Deruxtecan-dlnk (Datroway) Updates 2025: Uses in cancer, Side effects, Dosage, Expectations and More

oncodaily.com/drugs/datopo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DatopotamabDeruxtecanDlnk #Datroway #LungCancer @NSCLC
Datopotamab Deruxtecan-dlnk (Datroway) Updates 2025: Uses in cancer, Side effects, Dosage, Expectations and More - OncoDaily
Learn about Datopotamab Deruxtecan-dlnk (Datroway), its uses, side effects, dosage, and what to expect during treatment.
oncodaily.com
July 20, 2025 at 1:53 PM
mskdeptofmed.bsky.social
Breaking: The FDA approved datopotamab deruxtecan for unresectable or metastatic HR+/HER2-negative #breastcancer. Congrats to @mskcancercenter.bsky.social's Komal Jhaveri, one of the lead accruers of the TROPION Breast 01 trial. www.fda.gov/drugs/resour...
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult...
www.fda.gov
January 17, 2025 at 9:14 PM
drsgraff.bsky.social
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis academic.oup.com/oncolo/artic...
#SuppOnc #DatoDXd @hoperugo.bsky.social
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis
Abstract. Oral mucositis/stomatitis (hereafter stomatitis) is a common dose-limiting toxicity seen with various classes of cancer treatment. Symptoms assoc
academic.oup.com
April 5, 2025 at 1:04 AM
elisabettabonzano.bsky.social
📌FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

www.fda.gov/drugs/resour...
@oncoalert.bsky.social #OncoAlertAF
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult...
www.fda.gov
January 18, 2025 at 9:49 AM
elisaagostinetto.bsky.social
FDA approved Dato-DXd for HR+/HER2-neg pretreated metastatic #breastcancer based on results of Tropion-Breast01

@oncoalert.bsky.social

www.fda.gov/drugs/resour...
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult...
www.fda.gov
January 18, 2025 at 9:41 AM
oncodaily.bsky.social
FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-Mutated Non-Small Cell Lung Cancer
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Dato-DXd #EGFR #NSCLC #LungCancer
FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-Mutated Non-Small Cell Lung Cancer - OncoDaily
FDA approves datopotamab deruxtecan-dlnk for pretreated EGFR-mutant NSCLC after EGFR-TKI + plat therapy; 45 % ORR, 6.5month DOR.
oncodaily.com
June 25, 2025 at 2:08 PM
cancercommunicator.com
Datopotamab deruxtecan receives #FDA approval for previously treated advanced EGFRm+ NSCLC. #lungcancer #LCSM #medsky #oncsky #cansky www.cancercommunicator.com/post/datopot...
Datopotamab Deruxtecan Receives Accelerated FDA Approval for Previously Treated EGFR-Mutated NSCLC
On June 23, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway) for the treatment of adult patients with locally advanced or metast...
www.cancercommunicator.com
June 23, 2025 at 8:09 PM
marlowetessmer.bsky.social
Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models @mdanderson.bsky.social @theaacr.bsky.social aacrjournals.org/clincancerre...
Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models
AbstractPurpose:. Datopotamab deruxtecan (Dato-DXd) is a humanized anti–trophoblast cell-surface antigen-2 (TROP2) IgG1 mAb linked to a potent topoisomerase I inhibitor payload (DXd). Dato-DXd has alr...
aacrjournals.org
February 3, 2025 at 4:36 PM
onclive.bsky.social
BREAKING‼️@US_FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer #bcsm #oncology #FDAapproved onclive.com/view/fda-app...
January 17, 2025 at 6:48 PM
oncbrothers.bsky.social
Datopotamab deruxtecan now #FDA approved off #TROPIONBreast01: #DatoDXd Vs Chemo post 1-2L HR+ mBC

- ⏰ to 1st Rx: 8.2 vs 5mos (favoring Dato)
- ⬆️ PFS 6.9mos vs 4.5 mos
- Better AE + QoL favoring DatoDXd
- AEs: Fatigue, infusion reactions, stomatitis

#bcsm #OncSky #MedSky
January 17, 2025 at 6:36 PM
ascopost.bsky.social
The TROPION-Lung05 trial finds that datopotamab deruxtecan shows encouraging activity in advanced/metastatic NSCLC with actionable genomic alterations after prior targeted therapy and chemotherapy. #LungCancer #OncologyResearch ascopost.com/news/january...
February 6, 2025 at 3:29 PM
linglingtian.bsky.social
🧪 New study protocol published!
TROPION-Lung14 (phase III) evaluates osimertinib + datopotamab deruxtecan vs osimertinib alone in 1L EGFR-mutated advanced NSCLC.
Could combination therapy reshape first-line treatment?
🔗 Read more: buff.ly/pp3eAk2
#Oncology #LungCancer #NSCLC #ClinicalTrials #EGFR
June 3, 2026 at 7:00 AM
oncodaily.bsky.social
A new ADC is now available to treat the most common subtype of breast cancer - Paolo Tarantino
@ptarantinomd.bsky.social
@fda.gov

oncodaily.com/science/paol...

#BreastCancer #Cancer #DatopotamabDeruxtecan #Medicine #OncoDaily #Oncology #TB01trial #Health
Paolo Tarantino: A new ADC is now available to treat the most common subtype of breast cancer - OncoDaily
Paolo Tarantino: A new ADC is now available to treat the most common subtype of breast cancer / Breast Cancer, cancer, datopotamab deruxtecan, OncoDaily,
oncodaily.com
January 19, 2025 at 4:50 PM
oncoalert.bsky.social
NEWS FROM INDUSTRY: UPDATE ON TROPION-Breast02 #BreastCancer
Source European Pharmaceutical Review, Astrazeneca, Daiichi Sankyo

www.europeanpharmaceuticalreview.com/news/266702/...

The phase III TROPION-Breast02 trial showed that the ADC Datopotamab Deruxtecandlnk significantly improved OS & PFS
October 6, 2025 at 10:44 AM
rsm2800.bsky.social
FDA approves datopotamab deruxtecan-dlnk today. Good to have more options for patients with HR+/HER2- metastatic breast ca in lieu of traditional cytotoxic chemo www.fda.gov/drugs/resour...
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult...
www.fda.gov
January 17, 2025 at 6:53 PM
medicine.stitches.today
Datopotamab deruxtecan showed promising, lasting anti-tumor effects in advanced lung cancer patients despite extensive previous treatments.

by Sands J, Ahn MJ (...) Paz-Ares L et 20 al. in J Clin Oncol #MedSky

📖 read the article: https://ascopubs.org/doi/10.1200/JCO-24-01349
January 15, 2025 at 6:35 AM
drsgraff.bsky.social
🚨Kicking off 2025 with a new approval! FDA Approves Dato-DXd in HR+/HER2– Breast Cancer targetedonc.com/view/fda-appro… @oncoalert.bsky.social www.targetedonc.com/view/fda-app...er
FDA Approves Dato-DXd in HR+/HER2– Breast Cancer
As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer.
www.targetedonc.com
January 17, 2025 at 7:02 PM
dr-rshatsky.bsky.social
After all the experience I’ve had with Dato D’xd I JUST found out they named it Datroway. Why was that so hush hush for so long?? #MedSky #CanSky #OncSKy www.clinicaloncology.com/Solid-Tumors...
FDA Approves Datroway for Unresectable or Metastatic, HR-positive, HER2-negative Breast Cancer
The FDA has approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo), a Trop-2−directed antibody and topoisomerase inhibitor conjugate, for adult ...
www.clinicaloncology.com
January 23, 2025 at 2:29 PM
sciencex.bsky.social
A global phase III trial found that datopotamab deruxtecan nearly doubled progression-free survival and improved overall survival in patients with advanced triple-negative breast cancer. doi.org/hbxf94
Global trial shows novel treatment for triple-negative breast cancer nearly doubles survival
A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National Cancer Centre Singapore, has demonstrated a significant breakthrough in improving the survival of patients with untreated, advanced triple negative breast cancer (TNBC) using the novel antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd).
medicalxpress.com
April 16, 2026 at 8:21 PM
valdesan.bsky.social
datopotomab deruxtecan witdraws request for approval for treatment of nsclc. Focuses on egfr mutation, however same problem of lack of strong evidence compared to SOC. #oncsky finance.yahoo.com/news/datopot...
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J., November 12, 2024--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have submitted a new Biologics License Application (BLA) for accelerated approval in th...
finance.yahoo.com
November 12, 2024 at 10:42 AM
natrevdrugdiscov.nature.com
FDA new drug approvals in Q1 2025 tinyurl.com/5n8ak54h

Only 7 new drugs were approved by the FDA in Q1, but 2 are potential blockbusters - the sodium channel inhibitor suzetigrine for pain and TROP2-targeted ADC datopotamab deruxtecan for breast cancer
Table of new drugs approved in Q1
April 14, 2025 at 1:56 PM